Chronic allograft dysfunction: Major contributing factors

Iranian Journal of Kidney Diseases

Volumn 6, Issue 2, 2012, Pages 88-93

  Ganji, Mohammad Reza ^a   Haririan, Abdolreza ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitor; Chronic allograft dysfunction; Interstitial fibrosis; Tubular atrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ATROPHY; CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; GLOMERULONEPHRITIS; HUMAN; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT;

CALCINEURIN; CHRONIC DISEASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PRIMARY GRAFT DYSFUNCTION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84857844328     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol. 2009;5:513-9.
2. Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10:464-71.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-33.
4. Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am J Transplant. 2011;11:687-92.
5. Nankivell BJ, Wavamunno MD, Borrows RJ, et al. Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant. 2007;7:366-76.
6. Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ. Stable kidney function in the seconddecade after kidney transplantation while on cyclosporinebased immunosuppression. Transplantation. 2007;83: 722-6.
7. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant. 2011;11:698-707.
8. Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DE, Matas AJ. Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation. 1999;68:1842-6.
9. Rush DN, Cockfield SM, Nickerson PW, et al. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. Transplantation. 2009;88:897-903.
10. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant. 2010;10:2066-73.
11. Mengel M, Chang J, Kayser D, et al. The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. Am J Transplant. 2011;11:708-18.
12. Brouard S, Renaudin K, Soulillou JP. Revisiting the natural history of IF/TA in renal transplantation. Am J Transplant. 2011;11:647-9.
13. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant. 2007;7:408-15.
14. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007;7:864-71.
15. Miura M, Ogawa Y, Kubota KC, et al. Donor-specific antibody in chronic rejection is associated with glomerulopathy, thickening of peritubular capillary basement membrane, but not C4d deposition. Clin Transplant. 2007;21(Suppl 18):8-12.
16. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-60.
17. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9:2520-31.
18. Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant. 2010;10:2223-30.
19. McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant. 2007;7:1201-8.
20. Hidalgo LG, Campbell PM, Sis B, et al. De novo donorspecific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9:2532-41.
21. Haririan A, Kiangkitiwan B, Kukuruga D, et al. The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant. 2009;9:2758-67.
22. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527-35.
23. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant. 2007;7:2748-56.
24. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-75.
25. Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257-62.
26. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233-42.